Urologia

Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	NCT Number
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Prof. Doutor Carlo Greco	Recrutamento	NCT02570919

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital CUF Descobertas Rua Mário Botas 1998- 018 Lisboa - Portugal	Dr. António Quintela	Recrutamento	2018-001967-22
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Jorge Oliveira	Recrutamento	2018-001967-22

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Lusíadas Lisboa Rua Abílio Mendes 1500-468 Lisboa - Portugal	Dr. Paulo Cortes	Recrutamento	2017-003344-21
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Filipa Carneiro	Recrutamento	2017-003344-21

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Lusíadas Lisboa Rua Abílio Mendes 1500-468 Lisboa - Portugal	Dr. Paulo Cortes	Recrutamento	2017-002932-18

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Lisboa Ocidental Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide - Portugal	Dra. Ana Martins	Recrutamento	2020-003106-31

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira R. dos Cutileiros 114, Creixomil - Portugal	Dra. Carolina Carvalho	Recrutamento	2020-000348-77

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira R. dos Cutileiros 114, Creixomil - Portugal	Dra. Vânia Grenha	Recrutamento	2020-002646-16

ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EucraCT
Hospital CUF Tejo Av. 24 de Julho 171A, 1350-352 Lisboa - Portugal	Prof. Dr. Mário Fontes e Sousa	Recrutamento	2020-003681-40